Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Natalia Reoutova, 07 Jan 2020

A prospective cohort study of mothers taking antiepileptic drugs (AEDs) and their breastfed infants has found substantially lower AED concentrations in infant vs maternal blood, with nearly half of all obtained AED concentrations in nursing infants being less than the lower limit of quantification (LLoQ).

5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Superficial chemical peels relatively safe for darker skins

30 Aug 2018

Superficial chemical peel treatments are safe for darker skins, yielding relatively low complication rates, a recent study has shown. However, those with skin type VI are at higher risk of adverse events.

Researchers performed a retrospective analysis of 473 chemical peel treatments performed on 132 patients (mean age 40.3±10.9 years), whose skin types ranged from type III to type VI. Each patient received a mean of 3.5 peels, though most of the treatments were performed on females (388 vs 85).

Eighteen treatments (3.8 percent) resulted in either short-term (1.1 percent) or long-term (2.7 percent) side effects. The median duration of the side effects was 4.5 weeks and the most common complications were prolonged crust (2.3 percent) and erythema (1.9 percent).

Side effects were most commonly observed in those with skin type IV (5.4 percent), type III (2.7 percent) and type VI (12.5 percent).

Relative to skin type III, those with type VI were at significantly higher risks of side effects (odds ratio [OR], 5.14; 95 percent CI, 1.21–21.8; p=0.0118), while those with skin type V demonstrated a nonsignificantly lower risk (OR, 0.67; 0.15–3.05; p=0.0659).

Side effects were most frequent in single peels (4.7 percent), treatments that used glycolic acid (6.03 percent) and in patients who had previously received chemical peels. On the other hand, peels performed in the winter had a nonsignificantly lower likelihood of resulting in side effects than those performed in the spring (OR, 0.13 0.02–1.02; p=0.078).

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Natalia Reoutova, 07 Jan 2020

A prospective cohort study of mothers taking antiepileptic drugs (AEDs) and their breastfed infants has found substantially lower AED concentrations in infant vs maternal blood, with nearly half of all obtained AED concentrations in nursing infants being less than the lower limit of quantification (LLoQ).

5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.